Analyst Price Targets — ILMN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 17, 2026 12:45 pm | Puneet Souda | Leerink Partners | $210.00 | $186.89 | TheFly | Illumina price target raised to $210 from $175 at Leerink |
| July 14, 2026 10:51 am | Kyle Mikson | Canaccord Genuity | $190.00 | $190.05 | TheFly | Illumina price target raised to $190 from $140 at Canaccord |
| June 29, 2026 11:00 am | — | Guggenheim | $200.00 | $176.55 | TheFly | Illumina price target raised to $200 from $180 at Guggenheim |
| June 26, 2026 10:27 am | — | Bernstein | $185.00 | $177.65 | TheFly | Illumina resumed with a Market Perform at Bernstein |
| June 1, 2026 11:27 am | — | Guggenheim | $180.00 | $162.96 | TheFly | Illumina price target raised to $180 from $170 at Guggenheim |
| May 14, 2026 8:23 pm | — | RBC Capital | $170.00 | $143.24 | TheFly | Illumina resumed with an Outperform at RBC Capital |
| May 14, 2026 9:05 am | Illumina to Outperform | Daiwa | $155.00 | $145.00 | TheFly | Illumina upgraded to Outperform from Neutral at Daiwa |
| May 1, 2026 10:41 am | — | Canaccord Genuity | $140.00 | $126.74 | TheFly | Illumina price target lowered to $140 from $150 at Canaccord |
| May 1, 2026 9:28 am | — | Barclays | $122.00 | $126.74 | TheFly | Illumina price target raised to $122 from $110 at Barclays |
| February 9, 2026 12:01 pm | — | Piper Sandler | $170.00 | $119.72 | TheFly | Illumina price target lowered to $170 from $195 at Piper Sandler |
Latest News for ILMN
Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of…
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other…
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.